Myelofibrosis physical examination: Difference between revisions
Jump to navigation
Jump to search
(→HEENT) |
|||
| Line 19: | Line 19: | ||
===HEENT=== | ===HEENT=== | ||
*Lymphadenopathy which may involve the head and neck | *Lymphadenopathy which may involve the head and neck<ref name="pmid28011890">{{cite journal |vauthors=Panda A, Chandrashekhara SH, Nambirajan A, Mishra P |title=Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: initial presentation and 2 years follow-up |journal=BMJ Case Rep |volume=2016 |issue= |pages= |date=December 2016 |pmid=28011890 |doi=10.1136/bcr-2016-217854 |url=}}</ref><ref name="pmid28781273">{{cite journal |vauthors=Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K |title=Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis |language=Japanese |journal=Rinsho Ketsueki |volume=58 |issue=7 |pages=772–775 |date=2017 |pmid=28781273 |doi=10.11406/rinketsu.58.772 |url=}}</ref><ref name="pmid30046414">{{cite journal |vauthors=Aljabry MS, Asiri S, Elsafi T, Elyamany G |title=Generalized lymphadenopathy secondary to isolated extramedullary hematopoiesis as an initial manifestation of primary myelofibrosis |journal=Hematol Rep |volume=10 |issue=2 |pages=7588 |date=May 2018 |pmid=30046414 |pmc=6036984 |doi=10.4081/hr.2018.7588 |url=}}</ref> | ||
* | *Signs of jaundice<ref name="pmid21162885">{{cite journal |vauthors=Song ZQ, Zhou LY |title=[A clinical analysis of six cases of portal hypertension secondary to primary myelofibrosis and review of literatures] |language=Chinese |journal=Zhonghua Nei Ke Za Zhi |volume=49 |issue=10 |pages=845–7 |date=October 2010 |pmid=21162885 |doi= |url=}}</ref><ref name="pmid1887177">{{cite journal |vauthors=Saad GM, de Almeida TV |title=[Idiopathic myelofibrosis] |language=Portuguese |journal=Rev Paul Med |volume=109 |issue=2 |pages=47–50 |date=1991 |pmid=1887177 |doi= |url=}}</ref><ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref> | ||
==References== | ==References== | ||
Revision as of 20:10, 4 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis physical examination On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis physical examination |
|
Risk calculators and risk factors for Myelofibrosis physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Patients with myelofibrosis usually appear anemic. Physical examination of patients with myelofibrosis is usually remarkable for splenomegaly, hepatomegaly, skin pallor, petechiae and ecchymoses, and lymphoadenopathy.
Physical examination
Appearance of the Patient
- Patients with myelofibrosis usually appear anemic.
Vital Signs
Skin
HEENT
References
- ↑ Shinar Y, Tohami T, Livneh A, Schiby G, Hirshberg A, Nagar M, Goldstein I, Cohen R, Kukuy O, Shubman O, Sharabi Y, Gonzalez-Roca E, Arostegui JI, Rechavi G, Amariglio N, Salomon O (June 2015). "Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis". Orphanet J Rare Dis. 10: 86. doi:10.1186/s13023-015-0298-6. PMC 4506767. PMID 26123310.
- ↑ Mitra D, Kaye JA, Piecoro LT, Brown J, Reith K, Mughal TI, Sarlis NJ (December 2013). "Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review". Cancer Med. 2 (6): 889–98. doi:10.1002/cam4.136. PMC 3892393. PMID 24403262.
- ↑ Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S (August 2013). "Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study". Leuk. Res. 37 (8): 911–6. doi:10.1016/j.leukres.2013.04.017. PMID 23684482.
- ↑ Finazzi G, Vannucchi AM, Barbui T (November 2018). "Prefibrotic myelofibrosis: treatment algorithm 2018". Blood Cancer J. 8 (11): 104. doi:10.1038/s41408-018-0142-z. PMC 6221891. PMID 30405096.
- ↑ Hofmann I, Geer MJ, Vögtle T, Crispin A, Campagna DR, Barr A, Calicchio ML, Heising S, van Geffen JP, Kuijpers M, Heemskerk J, Eble JA, Schmitz-Abe K, Obeng EA, Douglas M, Freson K, Pondarré C, Favier R, Jarvis GE, Markianos K, Turro E, Ouwehand WH, Mazharian A, Fleming MD, Senis YA (September 2018). "Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice". Blood. 132 (13): 1399–1412. doi:10.1182/blood-2017-08-802769. PMID 29898956. Vancouver style error: initials (help)
- ↑ Kc D, Falchi L, Verstovsek S (October 2017). "The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review". Ann. Hematol. 96 (10): 1595–1604. doi:10.1007/s00277-017-3099-2. PMC 5693670. PMID 28808761.
- ↑ Complications of primary myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 10, 2016
- ↑ Miyata T, Masuzawa M, Katsuoka K, Higashihara M (July 2008). "Cutaneous extramedullary hematopoiesis in a patient with idiopathic myelofibrosis". J. Dermatol. 35 (7): 456–61. doi:10.1111/j.1346-8138.2008.00502.x. PMID 18705835.
- ↑ Corella F, Barnadas MA, Bordes R, Curell R, Espinosa I, Vergara C, Alomar A (May 2008). "[A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis]". Actas Dermosifiliogr (in Spanish; Castilian). 99 (4): 297–300. PMID 18394406.
- ↑ Kwon KS, Lee JB, Jang HS, Chung TA, Oh CK (June 1999). "A case of cutaneous extramedullary hematopoiesis in myelofibrosis with a preponderance of eosinophilic precursor cells". J. Dermatol. 26 (6): 379–84. PMID 10405485.
- ↑ Ruberto E, Espinola R, Brusco J, Bacchiocchi M, Zoppi J, Paz R (April 1995). "[Idiopathic myelofibrosis with extramedullary hematopoiesis foci in the skin and testicles. Report of a case]". Sangre (Barc) (in Spanish; Castilian). 40 (2): 157–60. PMID 7784946.
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Panda A, Chandrashekhara SH, Nambirajan A, Mishra P (December 2016). "Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: initial presentation and 2 years follow-up". BMJ Case Rep. 2016. doi:10.1136/bcr-2016-217854. PMID 28011890.
- ↑ Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K (2017). "Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis". Rinsho Ketsueki (in Japanese). 58 (7): 772–775. doi:10.11406/rinketsu.58.772. PMID 28781273.
- ↑ Aljabry MS, Asiri S, Elsafi T, Elyamany G (May 2018). "Generalized lymphadenopathy secondary to isolated extramedullary hematopoiesis as an initial manifestation of primary myelofibrosis". Hematol Rep. 10 (2): 7588. doi:10.4081/hr.2018.7588. PMC 6036984. PMID 30046414.
- ↑ Song ZQ, Zhou LY (October 2010). "[A clinical analysis of six cases of portal hypertension secondary to primary myelofibrosis and review of literatures]". Zhonghua Nei Ke Za Zhi (in Chinese). 49 (10): 845–7. PMID 21162885.
- ↑ Saad GM, de Almeida TV (1991). "[Idiopathic myelofibrosis]". Rev Paul Med (in Portuguese). 109 (2): 47–50. PMID 1887177.
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.